Co-Targeting PD-1 and IL-33/ST2 Pathways for Enhanced Acquired Anti-Tumor Immunity in Breast Cancer.

Although a slight increase in the percentages of CD69 + , NKG2D + , and FasL + CD3 + CD49b − T lymphocytes in the tumor microenvironment of WT mice after anti-PD-1 treatment were observed compared to untreated WT mice, the difference did not reach statistical significance. 3.

also in 111,027 other papers